title: The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients.
abstract: Pulmonary arterial hypertension (PAH) is a complex disorder in which pulmonary arterial obstruction leads to elevated pulmonary arterial resistance and right ventricular failure. Normal physiologic changes that occur during pregnancy and immediately postpartum may produce fatal consequence in PAH patients. Pregnancy in patients with PAH has a high maternal mortality, estimated at 30-56%. Contemporary estimates of mortality are better but still prohibitively high. Current guidelines recommend that pregnancy be avoided or terminated early in women with PAH. Some patients, despite counselling by their physician, choose to continue with their pregnancy. In addition, some women first present with PAH during pregnancy leading to complex management issues in a high-risk patient. PAH-specific therapies may allow patients to better tolerate pregnancy. These patients should be treated by experienced physicians at tertiary care centres. This review article will focus on the management of the pregnant PAH patient and the preventative options available for this high-risk cohort.
authors: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. cool.hsu@msa.hinet.net
authors: C-H
authors: CH
authors: Hsu
authors: M
authors: M
authors: Gomberg-Maitland
authors: C
authors: C
authors: Glassner
authors: J-H
authors: JH
authors: Chen
mesh_terms: D000032:Abortion, Therapeutic / Q000592:standards; D011464:Epoprostenol / Q000627:therapeutic use; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D005865:Gestational Age; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D010879:Piperazines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D011256:Pregnancy Outcome; D018566:Pregnancy, High-Risk; D011687:Purines / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D011464:Epoprostenol